NEW YORK, April 24 - Yamanouchi pharmaceuticals, Japan's third-largest drugmaker, plans to double its commitment to genomics over the next five years to 50 billion yen, or $411.8 million, Reuters reported from Tokyo on Tuesday.

The Tokyo-based company, which has invested four to five billion yen annually over the last few years, said it hopes to invest in genomics in order to find new drug targets and to catch up with US rivals, Reuters said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.